Fexaramine is a gut-restricted agonist at farnesoid X receptors (FXRs) that displays anti-obesity activity. Fexaramine alters bile acid composition, decreases weight gain and glucose production, and increases white adipose thermogenesis in animal models.
| Cas No. | 574013-66-4 |
|---|---|
| Purity | ≥98% |
| Formula | C32H36N2O3 |
| Formula Wt. | 496.65 |
| IUPAC Name | Methyl (2E)-3-{3-[(cyclohexylcarbonyl){[4'-(dimethylamino)-4-biphenylyl]methyl}amino]phenyl}acrylate |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | F1992 Info Sheet PDF |
|---|
Fang S, Suh JM, Reilly SM, et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med. 2015 Feb;21(2):159-65. PMID: 25559344.
Downes M, Verdecia MA, Roecker AJ, et al. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol Cell. 2003 Apr;11(4):1079-92. PMID: 12718892.
